The platform streamlines clinical trials through efficient data collection, planning, and patient access, accelerating the development of investigational therapies for hard-to-treat cancers. Its first trial, focused on triple-negative breast cancer, is already underway, evaluating the safety and efficacy of immunotherapy combined with chemotherapy.

The initiative involves a network of delivery partners including Austin Health, Alfred Health, and Monash Health, and engages leading clinical trial teams across Melbourne, regional Victoria, and Australia.

This momentum builds on BioNTech’s broader investment in Victoria through a strategic partnership with mRNA Victoria, which includes establishing  a state-of-the-art mRNA manufacturing facility at La Trobe University’s Bundoora campus. This strategic partnership will support clinical-scale manufacturing and R&D of investigational mRNA-based medicines.

Victoria is now the only location globally where both mRNA leaders, Moderna and BioNTech, have based R&D and manufacturing operations. This milestone reflects the state’s growing reputation as a destination of choice for global biotech investment and collaboration.

The Victorian Government has invested $5 million to drive growth in clinical trials, enabling industry-sponsored trials and supporting the commercialisation of new therapies. Over the past decade, more than $1 billion has been invested in health and medical research, fostering breakthroughs and creating jobs across the sector.

Together, these investments strengthen Victoria’s role in next-generation healthcare and create new export opportunities for the state’s world-leading life sciences ecosystem.